Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pliant Therapeutics, Inc. - Common Stock
(NQ:
PLRX
)
1.610
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pliant Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
May 21, 2025
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 08, 2025
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
May 01, 2025
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX
April 25, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
April 21, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
April 17, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
April 07, 2025
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
March 30, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX
March 26, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
March 23, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
March 19, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
March 17, 2025
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
March 15, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
March 13, 2025
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
March 09, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
March 05, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results
March 03, 2025
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
March 03, 2025
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
February 18, 2025
From
The Schall Law Firm
Via
Business Wire
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
February 13, 2025
Pliant has initiated assembly of outside panel of world-renowned experts to review BEACON-IPF trial data
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
February 07, 2025
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 22, 2025
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer
January 22, 2025
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
January 02, 2025
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
November 21, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
November 18, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 07, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in the Stifel Healthcare Conference
November 06, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024
October 17, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
October 01, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.